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ArticleBalance of Active, Passive, and Anatomical Cardiac
Properties in Doxorubicin-Induced Heart FailureAlexandre Lewalle,1 Sander Land,1 Jort J. Merken,2 Anne Raafs,2 Pilar Sepu´lveda,3 Stephane Heymans,2
Jos Kleinjans,4 and Steven A. Niederer1,*
1Department of Biomedical Engineering, St Thomas’s Hospital, King’s College London, London, United Kingdom; 2Department of Cardiology,
Maastricht University, Maastricht, the Netherlands; 3Regenerative Medicine and Heart Transplantation Unit, Instituto de Investigacio´n Sanitaria
La Fe, Valencia, Spain; and 4Department of Toxicogenomics, Maastricht University, Maastricht, the NetherlandsABSTRACT Late-onset heart failure (HF) is a known side effect of doxorubicin chemotherapy. Typically, patients are diag-
nosed when already at an irreversible stage of HF, which allows few or no treatment options. Identifying the causes of compro-
mised cardiac function in this patient group may improve early patient diagnosis and support treatment selection. To link
doxorubicin-induced changes in cardiac cellular and tissue mechanical properties to overall cardiac function, we apply a multi-
scale biophysical biomechanics model of the heart to measure the plausibility of changes in model parameters representing the
passive, active, or anatomical properties of the left ventricle for reproducing measured patient phenotypes. We create represen-
tative models of healthy controls (N¼ 10) and patients with HF induced by (N¼ 22) or unrelated to (N¼ 25) doxorubicin therapy.
The model predicts that HF in the absence of doxorubicin is characterized by a 2- to 3-fold stiffness increase, decreased tension
(0–20%), and ventricular dilation (of order 10–30%). HF due to doxorubicin was similar but showed stronger bias toward reduced
active contraction (10–30%) and less dilation (0–20%). We find that changes in active, passive, and anatomical properties all
play a role in doxorubicin-induced cardiotoxicity phenotypes. Differences in parameter changes between patient groups
are consistent with doxorubicin cardiotoxicity having a greater dependence on reduced cellular contraction and less anatomical
remodeling than HF not caused by doxorubicin.SIGNIFICANCE Doxorubicin, a common chemotherapeutic drug, is a known cause of heart failure. The relative
significance of its molecular, cellular, and tissue physiological effects in shaping the long-term condition remains unclear.
Diagnosis and treatment options are hence severely limited, given the gap in understanding between symptoms and
underlying causes. This study aims to bridge this gap through computational biomechanical modeling, linking left-
ventricular mechanics with clinical measurements. By providing a framework for integrating and interpreting heart-failure
clinical measurements (either associated with or independent of doxorubicin), we seek to identify underlying mechanisms
specific to cardiotoxic heart failure. Ultimately, identifying these dominant mechanisms may help improve diagnosis,
therapies, and at-risk patient identification in this challenging patient group.INTRODUCTION
Doxorubicin is a common anthracycline chemotherapeutic
drug with multitudinous irreversible cardiotoxic side effects
that increase the risk of heart failure (HF) (1–3). The inci-
dence rate of congestive heart failure after anthracycline
treatment is dose-dependent and has been shown to be as
high as 9% (4–6). The study and clinical treatment of
patients is inherently challenging given the timescales forSubmitted April 16, 2019, and accepted for publication July 23, 2019.
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creativecommons.org/licenses/by/4.0/).the development of symptoms, which range from weeks to
years after cessation of chemotherapy. Cardiotoxic effects
are thus confounded with natural aging, lifestyle, and pre-
disposition to cardiovascular disease. Cardiotoxicity pa-
tients are identified as having a reduced left-ventricular
(LV) ejection fraction (LVEF, defined as the ratio of the
blood volume ejected per heartbeat into the circulation
heartbeat/the end-diastolic volume) (7). At this irreversible
stage, there are limited to no treatment options available
beyond conventional HF therapy. Identifying the changes
in cardiac properties that give rise to the reduced cardiac
function seen in these patients may facilitate the develop-
ment of improved monitoring, early HF detection, andBiophysical Journal 117, 2337–2348, December 17, 2019 2337
Lewalle et al.therapies tailored to the pathologies of this specific patient
group.
The multifariousness of doxorubicin cardiotoxicity con-
stitutes a major challenge for developing systematic treat-
ment strategies. At the subcellular molecular level,
doxorubicin facilitates the formation of free radicals and
reactive oxygen species, thereby generating significant
oxidative stress, particularly in mitochondria (8,9). This af-
fects a multitude of dependent pathways, resulting in inter-
ference with gene expression by inhibiting topoisomerases
(10), the degradation of mitochondrial function (11,12),
cardiomyocyte apoptosis (13), intracellular calcium dysre-
gulation (14,15), myofibrillar deterioration (16), the deteri-
oration of cardiomyocyte structure (1), and cardiac energy
homeostasis generally (2). These cellular-level effects
have consequences at a higher functional level. Doxorubicin
increases the ability of tumor cells to disintegrate the extra-
cellular matrix, thereby impairing tumor cell motility and
the structural integrity of the cardiac tissue (17). Reduced
LVEF suggests a deterioration in the contractile tension of
the muscle tissue. Early cardiac fibrosis has also been
observed in doxorubicin-treated patients with potential
impact on the passive mechanical tissue properties (18).
At the organ level, doxorubicin may also be associated
with dilation of the LV cavity (19). Despite the abundance
of research into all these aspects of cardiotoxicity, their rela-
tive importance in the overall development of HF is un-
known. Thus, the clinical treatment of the ensuing HF
generally focuses on alleviating symptoms independently
of underlying causes. There is presently no systematic meth-
odology for linking drug targets with long-term clinical out-
comes in this patient group (20).
The aim of this study is to identify characteristic changes
in cellular and material function, specific to this patient
group, that could be used for developing early identification
biomarkers or informing patient treatment. We propose to
combine known physiology, inherent physical laws, and
pressure, motion, and anatomical measurements within a
single biophysical framework to generate plausible esti-
mates of the dominant factors that give rise to cardiotoxic
HF. We used computational simulations of the cardiac cycle
to map principal clinical cardiac phenotypes routinely
measured in HF patients (the LVEF, the LV end-diastolic
diameter (LVEDD), and the maximal ejection pressure
(MEP)) onto underlying mechanistic properties. To repro-
duce the observed phenotype variations with maximal ob-
jectivity while acknowledging the scale of the complexity
of the physiological system, our analysis considered three
broad classes of cardiac features from a phenomenological
perspective: the strength of active contraction, passive me-
chanical properties, and anatomical dimensions of the LV.
Model parameters expressing these properties were con-
strained using LVEF, LVEDD, and MEP measurements, as
well as measurements of the collagen volume fraction
(CVF) performed on biopsies. Hence, by separately2338 Biophysical Journal 117, 2337–2348, December 17, 2019analyzing data from healthy and diseased patients, we
sought to determine 1) what alterations to mechanistic prop-
erties of healthy hearts can most plausibly account for the
development of the HF phenotypes and 2) whether such
alterations differ in HF due to doxorubicin compared to
HF resulting from other causes. Identifying the dominant
or even the most likely factors responsible for cardiotoxic-
ity-induced HF is an important first step in developing future
studies for at-risk patient identification, early diagnosis, and
treatment.MATERIALS AND METHODS
Clinical characterization
Patient cohorts
All patients were recruited at the Academic Hospital Maastricht, Maastricht
University Medical Centre in a study approved by the local ethics commit-
tee and adhering to the declaration of Helsinki. Three patient cohorts were
considered:
Cardiotoxic HF patients (HFC) (Table S1, N ¼ 22) were doxorubicin-
treated cancer patients with HF symptoms (e.g., dyspnea, fatigue, edema,
reduced LVEF). The HF symptoms developed typically 1 year or more after
the cessation of chemotherapy (average 6 5 6 years). HF treatments
involved a range of medications and dosage adapted to each patient accord-
ing to their body mass (Table S4). Average age¼ 555 13 years, body mass
index (BMI) ¼ 265 3 kg/m2, gender ¼ 23% male, 77% female.
Noncardiotoxic HF patients (HF0) (Table S2, N ¼ 25) were patients
suffering from HF (same symptoms as for HFC) with no history of chemo-
therapy. Average age ¼ 555 14 years, BMI ¼ 275 5 kg/m2, gender 32%
male, 68% female. HF treatments involved a range of medications and
dosage adapted to each patient according to their body mass (Table S5).
Healthy adults (HA) (Table S3, N ¼ 10) were average age ¼ 49 5 10,
BMI ¼ 275 4, gender ¼ 80% male, 20% female.
All the data reported in the manuscript were obtained when patients were
admitted to the hospital and diagnosed with idiopathic HF (i.e., excluding
ischemia or valvular disease as causes of HF). However, the cohorts were
heterogeneous in the sense that some patients were already undergoing
HF medical treatment while others were not. Unfortunately, this informa-
tion was not available.
Echography and hemodynamics measurements
The LVend-diastolic and end-systolic diameters (LVEDD, LVESD), cavity
wall thicknesses (interventricular septum (IVS) and LV posterior wall
(LVPW)), and LVEF were measured by standard transthoracic echocardio-
gram according to the American Society of Echocardiography guidelines
using commercially available ultrasound systems with phased-array
transducers Sonos 5500 or iE33 (Philips Medical Systems, Best, the
Netherlands).
Collagen
Endomyocardial biopsy samples were taken as part of the clinical treatment
for a selection of HF patients (HFC: n¼ 8, HF0: n ¼ 8) to measure collagen
content. Samples were dyed with Sirius red, and the CVF was calculated as
the fraction of dyed regions in the thin tissue slices. Biopsies were extracted
with no specific orientation and therefore provided no directional informa-
tion with respect to the muscle fibers.
We sought to relate changes in CVF to changes in passive mechanical
stiffness by performing a literature survey of biopsy-based comparisons
of patients with and without HF. The latter patient category yielded control
CVF levels, assumed to resemble healthy heart tissue.
Doxorubicin-Induced Heart FailureFinite-element model and simulation
Geometrical configuration
The unloaded LV was constructed as a finite-element mesh of concentric
semiellipsoids with eight elements in the azimuthal direction, six in
the apex-base direction, and two across the wall (Fig. 1 a). The wall
thickness was fixed at 10 mm, and the innermost (endocardial)
semiellipsoid was 60 mm long. Meshes with different endocardial
radii (nine values in the range 20–33 mm) were constructed to
simulate LV dilation. Muscle-fiber orientations within the tissue
were defined by imposing a rule-based configuration, with elevation an-
gles varying linearly across the wall, from 60 (epicardial surface)
to þ80 (endocardial) (21,22).FIGURE 1 General model structure and simulation workflow. (a) The
reference unloaded LV is represented as a semiellipsoidal mesh with
radius rendo. Mechanical properties are characterized by a maximal ten-
sion Tref and a passive stiffness scaling factor c1 (68). (b) The mechanical
deformation of the system upon application of a calcium transient (25) is
calculated numerically over the time course of several full cycles until
reaching a steady state (see the text for the Simulation Protocol) (22).
The ‘‘Windkessel model’’ represents the external circulation, parameter-
ized by an aortic-valve resistance z ¼ 4.7 kPa , s , 11, arterial
compliance c ¼ 0.02051/kPa, and peripheral arterial resistance
r ¼ 113.7 kPa , s , 11 (70). The aortic pressure before ejection
is pa. (c) The calculated steady-state phenotypes are the LV end-diastolic
and end-systolic volumes LVEDV and LVESV and the maximal ejection
pressure MEP. To see this figure in color, go online.Electromechanical coupling
LV contraction in the real heart is initiated by periodically releasing intra-
cellular calcium to generate tension. This cardiac cycle was simulated
within the computational framework described by Land et al. (23,24), using
a reference LV mesh to represent the unloaded LV.
The simulation is driven by a periodic (1 Hz) intracellular calcium stim-
ulus, derived from human-cell measurements (25), applied simultaneously
throughout the tissue (Fig. 1 b). Tissue contraction is modeled using a set of
ordinary differential equations describing the activation of force generation
by myosin cross-bridges and actin filaments. Maximal tension is character-
ized by the tension-scaling parameter Tref. The phenomenological represen-
tation of the physiological behavior includes length and velocity
dependences observed in muscle (22,26,27). The mechanical response is
determined by modeling the tissue as an elastic material that is trans-
verse-isotropic with respect to the muscle fibers and with a stiffness charac-
terized by the scaling parameter c1 (see Appendix A). The computed LV
deformation balances the locally generated tension, the viscoelastic
response, and external boundary conditions. The self-consistent solution
of the mechanics accounts for the transmission of the generated tension
throughout the tissue (including in directions perpendicular to the fibers)
as determined by the strain-energy functional and the imposed incompres-
sibility condition.
Computational method and boundary conditions
Partial differential equations describing the mechanical force balance were
solved subject to tissue incompressibility (28). Spatial boundary conditions
were defined by constraining the LV basal plane to lie perpendicular to the
apex-base axis, with one mesh node on the interior LV wall fixed in all di-
rections. Another node, located diametrically opposite on the LV interior,
was constrained to move along the axis connecting the fixed node to pro-
hibit rigid-body rotation. Pressure boundary conditions were defined by
specifying the aortic pressure pa, which was coupled to the LV via a
three-element Windkessel model (Fig. 1 b).
Simulation protocol
The cardiac cycle was simulated as previously described, implementing the
basic steps of the cardiac cycle (23,24). In summary, a phenomenological
model of diastolic filling governsLVinflation toward a set end-diastolic pres-
sure of 0.5 kPa (4mmHg). Upon stimulating themusclewith ameasured cal-
cium transient (25), the LV volume becomes fixed to simulate the closing of
themitral valve and the subsequent isovolumic contraction. Active tension is
thus generated within the tissue along the fiber directions (and transmitted
throughout the tissuemass as determined by the tissuemechanical properties
and the incompressibility constraint), resulting in a sharp LV pressure rise.
Upon reaching the preset aortic pressure pa, the isovolumic constraint is
removed, representing the opening of the aortic valve, and the Windkessel
model governs blood ejection from the LV until the volume-flow direction
is reversed (closing of the aortic valve). Fixing the LV volume again in
this state, isovolumetric relaxation is initiated, terminatingwhen theLVpres-
sure attains a preset diastolic pressure (0.2 kPa ¼ 1.5 mmHg). Diastolic
filling is then reactivated as the mitral valve reopens. The process is repeated
until the model converges to a steady-state limit cycle, typically after three
contractions (when the LV end-diastolic volume (LVEDV) varies by no
more than 0.5% between successive cycles). The mesh-node coordinates
and LV volume and pressure are recorded as functions of time over the limit
cycle. A representative pressure-volume loop is plotted in Fig. 1 c.Combining simulations and measurements
Parameter space
The simulation setup was guided by the clinical results summarized in
Table 1 to emulate the observed phenotypes. In summary, the principalBiophysical Journal 117, 2337–2348, December 17, 2019 2339
TABLE 1 Clinical Phenotypes Measured for each of the Patient Cohorts
Clinical
phenotype Healthy (N ¼ 10) HFC (N ¼ 22) p(HA/ HFC) HF0 (N ¼ 25) p(HA/ HF0) p (HFC/ HF0) pgrad (HFC/ HF0)
LVEDD (mm) 50 5 6 55 5 7 0.06 575 7 0.01 0.4 <105
LVESD (mm) 35 5 6 46 5 8 0.003 475 10 0.001 0.8 <105
IVS (mm) 9.4 5 1.4 8.4 5 1.6 0.10 8.65 1.4 0.12 0.6 0.4
LVPW (mm) 9.3 5 1.3 8.6 5 1.2 0.16 8.65 1.2 0.12 1.0 1.0
MEP (mmHg) 1405 12 1345 18 0.35 1415 22 0.9 0.3 1.0
MinAP (mmHg) 81 5 8 85 5 14 0.37 815 12 0.84 0.5 0.0004
LVEF (%) 58 5 3 35 5 13 <105 345 14 <105 0.6 ND
Heart rate (bpm) 68 5 15 78 5 18 (n ¼ 8) 0.16 665 11 (n ¼ 8) 0.8 0.05 1.0
CVF (%) ND 12 5 10 ND 8.45 5.6 ND 0.3 ND
Values indicate the means and SDs, measured for each of the patient cohorts, as illustrated in the histograms in Fig. S1: healthy hearts (N ¼ 10), HFC (N ¼ 22),
and HF0 (N¼ 25). The quoted p values evaluate the discrepancy between each HF cohort (HFC, HF0) and the healthy hearts. Collagen fractions were measured in
biopsies taken from patients in the HFC (n¼ 6) and HF0 (n ¼ 8) groups. No healthy-patient biopsies were available within this study. LVEDD, LVend-diastolic
diameter; LVESD, LV end-systolic diameter; IVS, interventricular septum thickness; LVPW, LV posterior wall thickness; MEP, maximum ejection pressure;
MinAP, minimum aortic pressure; LVEF, LV ejection fraction; HR, heart rate; CVF, collagen volume fraction; ND, no data.
Lewalle et al.phenotypes differentiating the three cohorts are LVEF, LVEDD, and
LVESD. Properties that determine LVEDD include the LV geometry, the
passive mechanical stiffness of the tissue, and the diastolic filling pressure.
In the absence of experimental data characterizing diastolic filling, we
assumed a constant end-diastolic pressure ped for all simulations and amal-
gamated it with the mechanical stiffness c1 into a phenomenological scaling
parameter: c1  c1/ped. The systolic properties represented by LVEF and
LVESD additionally require a consideration of the active tension magni-
tude, scaled phenomenologically by the model parameter Tref. Because
MEP was the same in all cohorts, the aortic pressure pa was assumed con-
stant. We therefore defined the model parameter space as comprising the
reference (unstrained) LV endocardial diameter 2  rendo and treating Tref
and c1 as phenomenological parameters that cumulate the entire ensemble
of cellular-level mechanisms defining active and passive mechanics.
We constructed a mesh of fixed basal radius rendo¼ 22.3 mm to represent
cohort HA but allowed rendo to vary to accommodate LV dilation in HF.
MEP and minimal aortic pressure (MinAP) values are similarly homoge-
neous across cohorts, and the aortic pressure was therefore set to a constant
pa¼ 15 kPa (112 mmHg). A constant wall thickness w¼ 10 mm, consistent
with the echo measurements, was also adopted in all the simulations.
The strength of active tension was varied by tuning the tension-scaling
parameter Tref (corresponding to maximal active tension, when all myosin
cross-bridges are bound to actin) around 120 kPa (as measured in isolated
myofibrils (29)). Passive stiffness was varied by tuning the stiffness-
scaling parameter c1 (Eq. 4) to match the simulated to the observed
LVEDD. The simulations were repeated to map the parameter space
defined by
8<
:
c1 ¼ 0:6. 8:0 kPa
Tref ¼ 80. 180 kPa
rendo ¼ 20:0. 33:0 mm
(1)
To confirm that these conditions satisfactorily covered the range of plau-
sible physiological scenarios, we checked that no significant domains of
this space were truncated by the choice of parameter bounds, as explained
in the Supporting Materials and Methods.
Comparing simulations and measurements
Each simulation outputs the time courses for the LV pressure, volume, and
node coordinates over a full steady-state cycle, thereby allowing a mapping
of the simulation parameters to the phenotype measurements:

c1; Tref ; rendo

/fLVEDD;MEP;LVEFg (2)2340 Biophysical Journal 117, 2337–2348, December 17, 2019Neither cohort can be represented by a unique parameter set, firstly
because of the phenotype variability and secondly owing to the ‘‘many-
to-one’’ nature of the mapping (Eq. 2). Our analysis, therefore, aimed to
determine the distribution of parameter transformations that plausibly
describe the development of HF as follows.
The analysis workflow is illustrated in Fig. 2 for the transition between
HA and HFC. Fig. 2 a compares the measured phenotypes, represented
by histograms, with a slice through the simulated data set corresponding
to constant rendo ¼ 22.3 mm, represented by black points plotted below
the histograms. Each simulation yields phenotype values that either
conform with one or both patient cohorts (when the values lie within the his-
togram ranges) or with neither (when the value lies outside the measure-
ment bounds).
We define a metric Q ˛ [0, 1] to quantify the degree of agreement
between a simulated and a measured phenotype for a given cohort, tak-
ing into account the variability of that phenotype within the cohort, as
illustrated in Fig. 2 b1. For a given value of x of a generic phenotype,
we define QðxÞhS1=S2, where S1 is the number of measurements
that are more distant than x from the distribution mean hxi and S2 is
the total number of measurements that are on the same side of hxi
as x, as indicated. Thus, Q ¼ 1 corresponds to a simulation for which
x coincides with hxi (representing maximal consistency), whereas
Q ¼ 0 signifies that the simulation lies outside the measurement range
(no consistency). An overall consistency metric Qtot ˛ [0, 1], covering
all the phenotypes, is then computed by multiplying the particular
Q values:
QtothQLVEDD  QMEP  QLVEF (3)
For illustration, the surface plots in Fig. 2 b2 map the functions Qtot ob-
tained separately for HA (green) and HFC (red), assuming rendo ¼ 22.3 mm
for both cohorts (i.e., the slice through the domain of Eq. 1 corresponding to
no LV dilation). The peaks in the landscape identify the regions of the
parameter space that are more strongly associated with one or the other
cohort.
Estimating parameter transitions from healthy to failing hearts
Using the Qtot distributions, we determined what parameter transforma-
tions, when applied to the healthy heart data set, could most plausibly
represent the development of HF. A ‘‘transformation,’’ in this context,
is defined as the ratio mxhx2=x1 between values of parameter x in
cohorts 1 and 2. To quantify the distance from cohort 1 to cohort 2,
we sample all possible pairs of points in the parameter space (Eq. 1),
calculate the corresponding mc1 , mTref , and mrendo ratios, and construct
the distribution P1/2ðmc1;mTref ;mrendoÞ of these ratios, weighted by the
FIGURE 2 Analysis workflow for mapping phenotypes differences to model parameter transformations. Simulated results are compared to the measured
phenotype distributions (LVEDD, MEP, and LVEF, taken from Fig. S1) for the healthy (a1–a3) and HFC cohorts (a4–a6). The black marks below the histo-
grams indicate the phenotypes predicted by the simulations (assuming constant rendo ¼ 22.3 mm and aortic pressure pa ¼ 15 kPa ¼ 112 mmHg). (b) The
consistency of individual simulations with the measured phenotype distributions was assessed through the metric Q. The principle for computing Q for a
generic phenotype distribution X is illustrated in (b1). Q ¼ S1/S2, with S1 and S2 representing integrals over the distribution, bounded by x and the distri-
bution mean hXi. (b2) Maps of Qtot ¼ QLVEDD  QME  QLVEF are then computed over the parameter space (Eq. 1) separately for each cohort. The distri-
bution P of parameter fold changes is computed for the pair of Qtot functions, as described in the Appendix B. A schematic illustration for two
one-dimensional functions D1(x) and D2(x) is shown in (c1), with the corresponding P(m) plotted in (c2). The two-dimensional Pðmc1;mTref ;mrendo ¼ 1Þ ob-
tained from (b2) is mapped out in (c3). The white dashed lines indicate the region where the decrease in Tref may be accounted for by an increase in the CVF,
as calculated in Appendix C. To see this figure in color, go online.
Doxorubicin-Induced Heart Failureassociated Qtot values for cohorts 1 and 2. The calculation, defined
formally in the Appendix B, is akin to calculating the cross correlation
between the two Qtot distributions. Fig. 2 c illustrates a representative
two-dimensional slice through this function, corresponding to the special
case of no LV dilation, i.e., PHA/HFCðmc1;mTref ;mrendo ¼ 1Þ. We interpret
the magnitude of P as measuring the relative ability of a given transition
to link the healthy to the diseased cohort.RESULTS
Clinical phenotypes
Phenotypes are compared in Table 1 (see histograms in
Fig. S1). The p-values associated with each mean were
calculated using two-sample t-tests to assess the discrep-
ancies between the healthy and each diseased cohort. Both
HFC and HF0 differ mostly markedly from HA in terms of
LVEF (a 40% decrease on average, p < 105), reflecting
the aptitude of LVEF as an indicator of HF. This
effect is accompanied by a significant increase in LVESD(p % 0.003) for both HF cohorts, also consistent with
impaired ejection. In contrast, MEP, MinAP, IVS, and
LVPW differ much less significantly between the cohorts
(p > 0.1). However, LVEDD is increased in HF by a factor
of order 10%, albeit less significantly for HFC (p ¼ 0.06)
than for HF0 (p ¼ 0.01). None of the phenotypes, including
LVEF, LVEDD, and LVESD, show any significant
difference when comparing HFC with HF0 directly
(p(HFC / HF0) > 0.3).
The above analysis, based purely on the individual
phenotype distributions, remains inconclusive with regard
to distinguishing between HFC and HF0 in terms of LVESD
and LVEDD. Fig. 3 compares the linear regression coeffi-
cients for each phenotype with respect to LVEF, with sig-
nificance (pgrad) assessed in the last column of Table 1
(30). No significant difference is again observed for
MinAP, MEP, IVS, or LVPW (pgrad > 0.4). However,
LVEDD, LVESD, and MinAP all display significant differ-
ences (p < 0.0005), which supports the exploration of theBiophysical Journal 117, 2337–2348, December 17, 2019 2341
FIGURE 3 Dependences of echocardiographic
and pressure phenotypes on the LVEF across the
patient cohorts: (a) interventricular septum thick-
ness, (b) LVPW thickness, (c) MEP, (d) minimal
aortic pressure, (e) LVEDD, (f) LVESD. The black
dashed lines represent the linear fit through all the
data points, and the dotted lines represent one SD
in the calculated slope above and below the line
of best fit. The p-values assess the deviation of
the fitted slope from zero. To see this figure in co-
lor, go online.
Lewalle et al.simulation parameter space defined by c1, Tref, and rendo
(Eq. 1).Collagen measurements
CVFwasmeasured in endocardial biopsies taken from a sub-
set ofHFC andHF0 patients (Fig. 4, a and b; Table 1). Healthy
CVF values were estimated from a literature survey of biopsy
measurements performed on patients testing negative for
cardiovascular disease (green data in Fig. 4, a and b, in which
the height of each data point represents the number of mea-
surements performed in the corresponding study (31–37)).
The mean CVF values for the HFC (10.3%) and HF0
(8.4%) cohorts differ by factors of 4.0 and 3.2, respectively,
relative to the mean healthy CVF (2.6%).
Variations in cardiac collagen content have been shown to
correlatewith passivemechanical stiffness (38–41).Although
other factors are important (e.g., collagen type and the
degree of cross-linking (42)), tissue stiffness is consistently
reported to increase with CVF, both in isolated cardiomyo-
cytes (34) and in the intact myocardium (43). An approxi-
mately proportional relationship is apparent in Fig. 4 e.2342 Biophysical Journal 117, 2337–2348, December 17, 2019Simulations
The main results of this work are shown in Fig. 5, which de-
picts PHA/HFC and PHA/HF0 as functions of mc1, mTref , and
mrendo. The horizontal axes represent increasing c1, the ver-
tical axes increasing Tref, and successive images denote LV
dilation with increasing rendo. We interpret each distribution
as a measure of the plausibility that a given combination of
changes in c1, Tref, and rendo reproduces the development of
the HF phenotypes, starting from the healthy configuration,
either in the presence (Fig. 5, a1–a6) or absence (Fig. 5, b1–
b6) of doxorubicin exposure.
The results for transitions to HFC and HF0 both display
a correlation between mc1 and mTref , i.e., a decrease in
Tref varies inversely with an increase in c1, with the
balance depending on the extent of LV dilation, as indi-
cated by the shift in the distribution along an upward
diagonal with increasing rendo. We observe a stronger dila-
tion in the case of the HF0 transition (mean hmrendoi ¼
1:21, averaged over the whole distribution) than for
HFC (hmrendoi ¼ 1:13).
To further constrain the computed distributions to the pa-
tient data, we related the biopsy CVF measurements to the
FIGURE 4 Histograms of the CVF distribution are shown for the (a) HFC
(red, mean 10.3 5 6.7%) and (b) HF0 patient cohorts (blue, mean 8.4 5
5.6%). The green data points in (a) and (b) represent the CVF measure-
ments done on healthy hearts, as reported in the literature (31–37) (mean
2.6%, weighted according to the number of measurements in each publica-
tion). The histograms in (c) and (d) represent the distributions of the CVF
ratios computed from (a) and (b), respectively. (e) A literature survey of the
relation between passive tissue stiffness and collagen volume fraction
(CVF) is given, comparing healthy hearts and cases of diastolic HF in
different species (34,43,64–66). The CVF and stiffness values are normal-
ized by their respective values corresponding to a healthy heart to highlight
the relative change in CVF and stiffness values. The dashed line has unit
gradient. To see this figure in color, go online.
FIGURE 5 Transition maps connecting (a1–a6) healthy to HFC hearts
and (b1–b6) healthy to HF0 hearts by varying c1 (horizontal axis), Tref
(vertical axis), and rendo (successive images) by factors mxhxðHFÞ=xðHAÞ.
The dotted white lines represent the average boundary over which the
lowering of Tref in the failing hearts may be explained by a reduction of
the MVF due to increased CVF (see text). The estimated CVF fold-change
distributions PDCVF(mCVF) (see Fig. 4, c and d), corresponding to the cohort
pairs in (a) and (b), are reproduced in (c) and (d), respectively. To see this
figure in color, go online.
Doxorubicin-Induced Heart Failurestiffness (horizontal) axes of Fig. 5, a and b. We estimated
the expected change in c1 by assuming a proportionality
with the change in CVF mCVF, as suggested by the literature
reviewed in Fig. 4 e. An effective distribution of mCVF was
calculated by cross-correlating the healthy and failing-heart
CVF distributions shown in Fig. 4 (see Appendix B for de-
tails). The resulting distributions PCVF (Fig. 4, c and d) char-
acterize the distributions of ratios mCVF that describe the
difference in CVF between the cohorts. For the cases of
both HFC and HF0, PCVF covers an order of magnitude,
with the bulk of the distribution being in the range
mCVF < 4, suggestive of a stiffness increase up to threefold
and a Tref decrease ranging from 0 to 20%. The HFC case,
however, is more strongly weighted toward lower values
(mCVF < 2), suggesting a stronger bias toward decreased
Tref (by 10–30%).Impact of CVF on contraction
Beside its effect on passive stiffness, an increase in CVF
may in principle also cause a reduction in net active ten-
sion generation by virtue of the fact that muscle tissue
is replaced by noncontractile collagen (cf. replacement
fibrosis (44)). The corresponding effective decrease in
Tref is independent of the ability of cardiac muscle to
generate tension.
The results of Fig. 5 indicate that the measured pheno-
types can be explained by a combination of changes in the
model parameters associated with the passive (c1) and active
properties (Tref). To assess the extent to which the effective
reduction in Tref can be accounted for purely as a result of
the CVF change, we assumed the simplest scenario, namely
an inverse correlation between CVF and the volume fraction
of the contracting myocardium, i.e., muscle volume fraction
(MVF) ¼ 1  CVF; and secondly, a linear scaling of theBiophysical Journal 117, 2337–2348, December 17, 2019 2343
Lewalle et al.contractile strength with MVF. We hence estimated the
decrease in active tension associated with a given increase
in c1 using the formula derived in the Appendix. The dashed
lines in Fig. 2 c3 represent the expected effective decrease in
Tref arising solely from an increase in collagen (where each
dashed line corresponds to a different value of healthy heart
CVF, serving as a reference value). The regions of the map
located above these dashed lines thus represent regimes
where the decrease in Tref can be explained in terms of
reduced MVF rather than through a reduction of muscular
contraction. In all the cases considered, this region covered
no more than 9% of the total integral. This supports the
hypothesis that the extent of decrease in Tref required to ac-
count for HF cannot be fully explained by a simple decrease
in muscle density. Consequently, a greater contribution to
the decrease in Tref must have other causes, e.g., sarcomere
density or alignment.Confounding factors
Owing to the natural heterogeneity of patient cohorts and
the limited scope of available measurements, our simula-
tions are inevitably approximations of the physiological sys-
tem. To assess the significance of some potential
confounding factors, we performed the following additional
simulations.
The recruited patient cohorts, summarized in Tables
S1–S3, show the HA controls being predominantly male
and the HFC and HF0 cohorts being more biased toward fe-
males (breast cancer patients). Among various gender de-
pendences reported in the cardiac system (45–48), one
particular difference is in the LV mass and LVEDV, which
are on average 70% of the values in males (49). To test
the potential impact of this discrepancy on our conclusions,
we repeated simulations after scaling the LV meshes to 89%
of their value (0.89 ¼ 0.701/3) in all dimensions to represent
‘‘female’’ meshes. Simulations were repeated and analyzed
as previously, using these smaller meshes for mapping the
HFC and HF0 data. The results (Fig. S3) show no qualitative
difference with those in Fig. 5.
The clinical measurements associate HF with a dilation of
the LV cavity. The long-axis dimension of the LV cavity was
not measured, and the simulations therefore assumed a con-
stant long-axis length of 60 mm. To estimate the potential
impact of LV elongation, we repeated the simulations and
analysis after scaling the long axis in proportion to rendo.
The results show no qualitative difference with our findings
(Fig. S4).
The LV filling pressure was assumed to be fixed for all the
simulations but is known to increase in HF (50,51). This
property was, however, not characterized in our patient
cohorts. To estimate the potential sensitivity of our conclu-
sions to this effect, we repeated the simulations by doubling
the filling pressure. As expected, the results display an in-
crease in the stiffness ratio mc1 (Fig. S5), but the general2344 Biophysical Journal 117, 2337–2348, December 17, 2019qualitative comparison between the HFC and HF0 results re-
mains unchanged, with the former showing a stronger
contribution from decreasing Tref.
Some authors have reported a modification of the fiber-
orientation distribution in cases of dilated cardiomyopathy
and after pressure overload, with fibers becoming more ob-
lique relative to the LV wall cross section (52,53). To assess
the potential impact of changes in fiber orientation on our
conclusions, we repeated simulations using the ‘‘dilated’’
mesh with rendo ¼ 30 mm, making the endocardial and
epicardial fiber directions either more oblique (þ10) or
more circumferential (10) relative to the baseline fiber
configuration. The effect on the simulated phenotypes was
generally minimal. In particular, the maximal change in
LVEF was 3% (Table S6), significantly less than the
>20% caused by HF. This effect arguably does not affect
our main qualitative conclusions.DISCUSSION
This study aimed to employ for the first time, to our
knowledge, a biomechanical model to provide a frame-
work for interpreting clinical data specifically in the
context of doxorubicin cardiotoxicity. By mapping compu-
tational simulations of the cardiac cycle onto clinically
accessible functional phenotypes, we evaluated the relative
contributions of changes in the passive, active, and
morphological LV properties to the onset of the mechani-
cal phenotypes characterizing doxorubicin-induced and
conventional HF. This in turn provided a means for identi-
fying patterns characteristic of doxorubicin-induced HF
specifically.
We found no difference in blood pressure in HF patients
who had or had not undergone doxorubicin chemotherapy.
On the other hand, differences in the correlations between
active, passive, and anatomical properties were detected
by quantifying the degree of consistency between simulated
and measured phenotypes. The results, summarized in
Fig. 5, suggest that depending on the extent of LV dilation,
HF cardiac phenotypes can be explained by a combination
of increased stiffness and decreased strength of muscle
contraction. In the case of patients with doxorubicin-
induced HF, the clinical data are more consistent with 1)
less LV dilation and 2) a predominance of reduced active
tension over increased passive stiffness compared to cases
of HF unrelated to chemotherapy.
The clinical effects of anthracyclines on cardiac function
are well known and documented (12,54–58). However, this
information has yet to turn into tailored or improved diag-
nosis and treatment. Experimentally, many in vivo and
ex vivo studies have been performed to examine immediate
or short-term drug impact (20,56,59,60). However, trans-
lating these findings to the clinical case that can take years
to manifest is challenging. The long-term nature of doxoru-
bicin cardiotoxicity also makes the systematic tracking—or
Doxorubicin-Induced Heart Failureretrospective reconstruction—of its development problem-
atic. This study, therefore, sought to detect first-order effects
by linking measurable pathophysiological cardiac mechani-
cal phenotypes to classes of mechanistic properties of the
heart and to yield insight into the dominant underlying
mechanisms.
Despite the simplifications inherent in the analysis, the re-
sults open potential perspectives for refining the diagnosis
and treatment options available to cardiotoxic HF patients
that are absent in current clinical practice. At present,
treatment for cardiotoxicity is instigated only once HF has
materialized. An improved awareness of the dominant
contributing factors leading to HF might facilitate the early
detection of those emerging factors before the onset of HF.
Treatment options may also be improved at later stages of
HF. As stated earlier, cardiotoxic HF patients currently
receive the same standard treatment for HF that focuses
on reversing external symptoms rather than targeting under-
lying causes (e.g., in cases of reduced LVEF, enhancing
LVEF through a reduction of arterial tension by b blockers
and ACE inhibitors) (7). Thus, a future treatment of cardio-
toxic HF may emphasize, through appropriate medication,
the restoration of contractile function. The choice of treat-
ment may be further guided by a closer monitoring of the
patients after the initiation of chemotherapy. For example,
an HF patient showing evidence of significant LV dilation
over the course of chemotherapy might potentially benefit
from a treatment targeting passive mechanical properties.
The drug pirfenidone inhibits transforming growth factor
b, which plays a central role in activating cardiac fibrosis
and has been shown in animal studies to reduce passive dia-
stolic stiffness while not restoring cardiac contractility (61).
By identifying classes of mechanisms that most likely ac-
count for HF phenotypes and by accommodating for the nat-
ural variety within cohorts, our approach sought to discern
trends that would escape notice in experiments focusing
on individual cases or specific mechanisms. Ultimately,
this may provide a framework for contextualizing known re-
sults and guiding more focused and detailed clinical inves-
tigation. Within this perspective, our results suggest a
greater emphasis on the deterioration of active contractile
function following from doxorubicin chemotherapy than
in more general cases of HF.Limitations
Like all patient modeling studies, this study has limitations.
HF is a heterogeneous disease, and we recruited limited pa-
tient numbers. Chemotherapy patients typically receive a
range of simultaneous medications rather than being limited
to doxorubicin (see Table S1). In addition, most of the pa-
tients referred to the cardiac clinic were already receiving
HF medication (Tables S4 and S5). Hence, we were limited
by the available clinical data, so we are not powered to
detect negative findings. Within this constraint and giventhe role of subjectivity in diagnosing HF, we aimed to mini-
mize bias by limiting the cohorts to patients recruited at the
same hospital.
Several authors have reported that a portion of the gener-
ated stress is exerted transversely relative to the mean local
fiber orientation (62,63). This study sought to identify first-
order effects on cardiac behavior, assuming that the genera-
tion of active stress occurs exclusively in the direction of the
muscle fibers (Eq. 5). The potential quantitative impact
of transverse stresses on our conclusions remains to be
explored.
A further limitation of the approach is its inability to
assign functional changes to specific molecular mecha-
nisms, which are instead encapsulated into phenomenolog-
ical representations of broad classes of phenomena. For
example, passive stiffness, quantified by c1, makes no
explicit reference to collagen or titin, known determinants
of cardiac tissue stiffness (34,41,43,64–66). Similarly, a
reduction in Tref can in principle result from a range of
different possible perturbations at the sarcomere level
(59,60,67). We hope that our findings may ultimately guide
future studies.CONCLUSION
We have created the first biomechanical models, to our
knowledge, to study long-term doxorubicin-induced cardi-
otoxicity. This provides a physiologically and physically
constrained framework for integrating and interpreting
clinical data in terms of underlying mechanisms. We
have used these models to provide bounds on the anatom-
ical, tissue, and cellular mechanisms that explain the
organ-scale clinical phenotypes within this challenging
patient group.APPENDIX A: TISSUE MECHANICS
The passive mechanical behavior was governed via the transverse-isotropic
strain-energy functional (68)
W ¼ 1
2
c1exp

c2E
2
11 þ c3

E222 þ E233 þ 2E223

þ 2c4

E212 þ E213

;
(4)
where E is the Lagrangian strain tensor expressed relative to the muscle fi-
ber and sheet directions and the parameters c2¼ 8, c3¼ 2, and c4 ¼ 4 char-
acterized the tissue anisotropy (69). Treating the prefactor c1 as a
phenomenological scaling factor for the overall passive tissue stiffness,
we allowed it to vary to preserve the ratios between the different stiffness
components. The total local stress tensor is hence defined as
T ¼ vWvEþ Tae1eT1 ; (5)
where e1 is the unit vector along the fiber direction. The self-consistent so-
lution of the mechanics problem in the simulations accounts for the trans-
mission of the generated tension throughout the tissue.Biophysical Journal 117, 2337–2348, December 17, 2019 2345
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DISTRIBUTIONS
Consider two functions D1 and D2 representing the distributions for some
metric (e.g., Q) for two cohorts 1 and 2. We characterize their distance
by considering, in turn, every possible pair of samples (x1, x2) taken from
D1 and D2 and constructing the distribution of the fold change m ¼ x2/x1
within each pair in going from x1 to x2. Formally, for continuous one-
dimensional functions D1(x) and D2(x), this fold-change distribution is ex-
pressed as
P1/2ðmÞDm ¼
Z
x
Z ðmþDmÞx
x0 ¼mx
D1ðxÞD2ðx0Þ dx dx0
By letting Dm/ 0, we obtain
P1/2ðmÞ ¼
Z
D1ðxÞD2ðmxÞx dx (6)
This calculation is illustrated for a generic one-dimensional case in Fig. 2,
c1 and c2, where PD1 ;D2ðmÞ is calculated for two generic one-dimensional
distributions D1(x) and D2(x), centered around x ¼ 0.5 and x ¼ 3, respec-
tively. The peak in PD1;D2ðmÞ represents the average fold change between
values sampled in D1 and D2 and is centered at x ¼ 6. The concept is
extended to the three-dimensional parameter space (Eq. 1). A two-dimen-
sional slice Pðmc1;mTref ;mrendo ¼ 1Þ is mapped out in Fig. 2 c3, correspond-
ing to the Qtot distributions in Fig. 2 b2.APPENDIX C: ESTIMATING TENSION REDUCTION
RESULTING FROM REDUCEDMUSCLE FRACTION
The observed increase in CVF between the healthy and failing hearts im-
plies a reduction of the MVF and, arguably, of the net maximal
tension that can be generated within the tissue by virtue of the fact
that there is less muscle tissue. This would argue for a reduction of
the effective Tref parameter in the model independently of the contractile
strength in the available muscle tissue. We sought to estimate to what
extent the reduction in muscle mass may account for the reduction in
the effective Tref. Assuming that Tref scales proportionally with
MVF ¼ 1  CVF, we have
THFCref
THAref
¼ 1 CVFHFC
1 CVFHA
In the light of the observed proportionality between the tissue stiffness
and the CVF in Fig. 4 e, we may write CVFHFC/CVFHA ¼ c1HFC/c1HA,
giving
THFCref
THAref
¼ 1
c1HFC
c1HA
 CVFHA
1 CVFHA (7)
Equation 7 therefore predicts that even if the contractile strength of mus-
cle tissue remains intact, the effective Tref decreases linearly with increasing
tissue stiffness c1, taken as a measure of CVF. The proportionality factor
depends on the CVF in healthy hearts (CVFHA). Any further decrease in
Tref is therefore expected to result from a genuine decrease in the contractile
strength of muscle tissue rather than simply the amount of muscle tissue
available.2346 Biophysical Journal 117, 2337–2348, December 17, 2019SUPPORTING MATERIAL
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